Calming the Storm

 

OUR MISSION

Serenity's mission is to change the pharmaceutical landscape with unorthodox ideas that are safe and effective.

We are beginning our venture by improving the capabilities of gene therapy, using a completely novel approach to immunomodulation.

Serenity will grow by forming strong relationships with academic and corporate organizations who share our values of integrity, honesty, and passion

 
edited.jpg

CARGOTEK™ PLATFORM

CargoTek™ improves gene therapies by inducing a state of tolerance and dampening adverse pro-inflammatory reactions. Our platform creates a state of "non-danger" for antigen presenting cells and allows activation of Treg cells, a potent immune dampening cell that releases immunosuppressive cytokines.

For gene therapies, our platform opens the door for multiple dose regimes while also enhancing the efficacy of the first dose. We can broaden the eligible patient population and significantly add value to the therapeutic.

Our platform technology allows us to develop a robust portfolio of next-generation biologics. Our platform can also address unmet needs in other therapeutic areas, such as protein based-therapeutics, cell therapies, and/or transplants.

 

OUR TEAM

We have assembled a team of experts with a deep understanding of molecular biology, the pharmaceutical industry and gene therapy.

 
Cody.JPG

CODY SHIRRIFF M.Sc

Co-founder and CEO

Co-inventor of CargoTek™, Serenity’s tolerance inducing platform technology. Entrepreneur and IndieBio accelerator alumnus. Research experience in intracellular stress pathways.

Spencer.JPG

SPENCER BERG M.Sc

Co-founder and CSO

Co-inventor of CargoTek™ Dedicated researcher with expertise in the fields of oncology and immunology. IndieBio alumnus.

CyganJennifer-22.jpg

JENNIFER CYGAN Ph.D

Chief Business Officer

20 years of business development experience with a focus on partnering therapeutic-enabling platforms

IMG-2476.JPG

JAMES CAMPBELL Ph.D

VP Preclinical Research

Expertise in proteostatic systems and recombinant protein production

dr-jonathan-blay-portrait.jpg

JONATHAN BLAY Ph.D

Pharmaceutical Science Advisor

30 years of research experience and gene therapy start-up founder.

holyoak-211x297.jpg

TODD HOLYOAK Ph.D

Protein Biochemistry Advisor

World expert in kinetics and protein structure. Performs high impact research with patentable outcomes

mark-kay_profilephoto.jpg

MARK A. KAY Ph.D M.D.

Gene Therapy Advisor

Pioneer in AAV gene therapy for hemophilia. Stanford professor in pediatrics and genetics

CAREERS

Coming soon 

CONTACT US

General Inquiries: contact@serenitybio.com

Partnership: partnership@serenitybio.com